Home
Categories
EXPLORE
True Crime
Comedy
Business
Society & Culture
Sports
Technology
History
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/8d/b8/0f/8db80f81-2247-4672-914d-289f9cb6f61b/mza_3544939216694081436.jpg/600x600bb.jpg
The Long Run with Luke Timmerman
Timmerman Report
186 episodes
1 week ago
Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.
Show more...
Science
RSS
All content for The Long Run with Luke Timmerman is the property of Timmerman Report and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.
Show more...
Science
https://i1.sndcdn.com/avatars-000334687557-gwdmq9-original.jpg
Ep187: Eric Fischer on Creating a New Class of Medicines
The Long Run with Luke Timmerman
1 hour 5 minutes 48 seconds
3 weeks ago
Ep187: Eric Fischer on Creating a New Class of Medicines
Eric Fischer, a professor at Dana-Farber Cancer Institute, on creating a new class medicines -- targeted protein degraders.
The Long Run with Luke Timmerman
Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.